| 摘要 |
<p>T he invention relates to polymorphic forms I and II forms which are characterized by the powder X ray diffraction model, the nuclear magnetic resonance spectrum of C13 and the infrared spectrum of figures 3, 5 and 8, and figures 4, 6 and 9, polymorphic forms I and II respectively. The invention also relates to the process for producing the polymorphic forms I and II through crystallisation of a saturated solution of 3-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl) -3,6-dihydro-2H-pyridine-1-yl] -(ethyl}-2-methyl-6,7, 8,9-tetrahydropyrido [1,2-a]pyrimidine-4-one as a base in solvents, alcohols, ketones, esters, ethers or halogenated derivatives, in adecuate pressure and temperature conditions.</p> |
